Three Sponsors

Hiding in plain sight – a case-based overview of amyloidosis

8 January 2026

Experts from the National Amyloidosis Centre in London examine three case studies, specifically focusing upon the symptoms that first aroused suspicion, the diagnostic tests that confirmed the condition, and the treatment options available to these patients.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.

Amyloidosis: a comprehensive guide for the cardiovascular team

8 January 2026

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Funding for this video has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

An assessment of new cholesterol targets. Measuring Lp(a): A ‘once in a lifetime’ opportunity

7 January 2026

Dr Julia Kenkre and Dr Holly Morgan explore the role of elevated lipoprotein(a) [Lp(a)] levels in cardiovascular risk, its measurement challenges, clinical implications, and the approach to management.